A Phase 1/2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory FLT3-ITD Positive Acute Myeloid Leukemia (AML)

Trial Profile

A Phase 1/2 Safety and Efficacy Study of Orally Administered PLX3397 in Adults With Relapsed or Refractory FLT3-ITD Positive Acute Myeloid Leukemia (AML)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Pexidartinib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Plexxikon
  • Most Recent Events

    • 21 Feb 2017 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.
    • 21 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 03 Mar 2016 Planned End Date changed from 1 Jun 2016 to 1 Mar 2017 according to the ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top